Join the club for FREE to access the whole archive and other member benefits.

Orthocell

Regenerative medicine company empowering the body to heal

It is a regenerative medicine company dedicated to the development of novel collagen medical devices and cellular therapies for the repair and regeneration of human tendons, bone, nerve and cartilage defects. 

CelGro® is a naturally derived collagen medical device for tissue repair. CelGro® is designed for use in multiple indications to augment the surgical repair of tendons, bone, peripheral nerves and articular cartilage. CelGro® has distinct competitive advantages over existing tissue repair devices, particularly in the areas of cell compatibility, mechanical properties (strength and ease of use) and facilitating high quality tissue repair making. CelGro® is approved for sale within the European Union for a range of dental bone and soft tissue procedures and is being readied for first approval in the US and Australia.

Ortho-ATI® is a first-in-class cell therapy for treatment of chronic tendon injuries.  The unique treatment uses each patient’s own tendon-derived cells to stimulate tendon regeneration, delivered via ultrasound guided injection under local anaesthetic. Ortho-ATI® addresses a significant unmet clinical need in the healing of tendons which are resistant to existing therapies.


Visit website: https://www.orthocell.com.au/

 Orthocell

 orthocell-ltd

 OrthocellLtd

Details last updated 21-Jun-2021

People at Orthocell

Paul Anderson

Founder and Managing Director of Orthocell Ltd

Orthocell News

Orthocell advances toward U.S. launch of nerve repair device Remplir™

Orthocell advances toward U.S. launch of nerve repair device Remplir™

Proactive Investor UK - 01-Dec-2024

Clinical success and FDA submission mark pivotal steps in redefining nerve regeneration solutions

Orthocell raises $17m to fast-track nerve repair device launch in the U.S.

Orthocell raises $17m to fast-track nerve repair device launch in the U.S.

Proactive Investor UK - 25-Oct-2024

Funding speeds U.S. entry and scales production as Orthocell advances global expansion

Returning function to paralysed upper limbs is the primary goal of Orthocell trial

Returning function to paralysed upper limbs is the primary goal of Orthocell trial

The Market Herald - 21-Jun-2021

Peripheral nerve repair could benefit 3 million patients every year